ELAN Stock Forecast 2025-2026
Distance to ELAN Price Targets
ELAN Price Momentum
10 Quality Stocks Worth Considering Now
Researching Elanco (ELAN) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on ELAN and similar high-potential opportunities.
Latest ELAN Stock Price Targets & Analyst Predictions
Based on our analysis of 13 Wall Street analysts, ELAN has a bullish consensus with a median price target of $15.00 (ranging from $12.00 to $18.00). The overall analyst rating is Buy (7.9/10). Currently trading at $10.55, the median forecast implies a 42.2% upside. This outlook is supported by 8 Buy, 7 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Jonathan Block at Stifel, projecting a 70.6% upside. Conversely, the most conservative target is provided by David Westenberg at Piper Sandler, suggesting a 13.7% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ELAN Analyst Ratings
ELAN Price Target Range
Latest ELAN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ELAN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 6, 2025 | Piper Sandler | David Westenberg | Neutral | Maintains | $12.00 |
| Feb 26, 2025 | UBS | Andrea Alfonso | Buy | Maintains | $17.00 |
| Feb 26, 2025 | Morgan Stanley | Erin Wright | Equal-Weight | Maintains | $13.00 |
| Feb 26, 2025 | Stifel | Jonathan Block | Buy | Maintains | $15.00 |
| Feb 26, 2025 | Barclays | Balaji Prasad | Overweight | Maintains | $19.00 |
| Feb 21, 2025 | Stifel | Jonathan Block | Buy | Maintains | $16.00 |
| Jan 29, 2025 | Morgan Stanley | Erin Wright | Equal-Weight | Maintains | $14.00 |
| Jan 7, 2025 | Stifel | Jonathan Block | Buy | Maintains | $18.00 |
| Dec 9, 2024 | UBS | Andrea Alfonso | Buy | Initiates | $18.00 |
| Dec 2, 2024 | Leerink Partners | Daniel Clark | Market Perform | Initiates | $14.00 |
| Nov 8, 2024 | Barclays | Balaji Prasad | Overweight | Maintains | $20.00 |
| Oct 28, 2024 | Barclays | Balaji Prasad | Overweight | Maintains | $19.00 |
| Sep 23, 2024 | Barclays | Balaji Prasad | Overweight | Maintains | $22.00 |
| Sep 19, 2024 | Morgan Stanley | Erin Wright | Equal-Weight | Downgrade | $15.00 |
| Sep 19, 2024 | Stifel | Jonathan Block | Buy | Reiterates | $20.00 |
| Jul 1, 2024 | Piper Sandler | David Westenberg | Neutral | Maintains | $16.00 |
| Jun 28, 2024 | Barclays | Balaji Prasad | Overweight | Maintains | $21.00 |
| May 13, 2024 | Piper Sandler | David Westenberg | Neutral | Reiterates | $19.00 |
| May 9, 2024 | Barclays | Balaji Prasad | Overweight | Maintains | $23.00 |
| Mar 12, 2024 | Piper Sandler | David Westenberg | Neutral | Reiterates | $18.00 |
Elanco Animal Health Inc. (ELAN) Competitors
The following stocks are similar to Elanco based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Elanco Animal Health Inc. (ELAN) Financial Data
Elanco Animal Health Inc. has a market capitalization of $5.22B with a P/E ratio of 15.5x. The company generates $4.44B in trailing twelve-month revenue with a 7.6% profit margin.
Revenue growth is -1.4% quarter-over-quarter, while maintaining an operating margin of +1.4% and return on equity of +5.5%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Elanco Animal Health Inc. (ELAN) Business Model
About Elanco Animal Health Inc.
Develops animal health pharmaceuticals and products.
Elanco generates revenue by developing and manufacturing a variety of therapeutic and preventative products for pets and livestock. The company offers medicines, vaccines, and wellness products that are essential for veterinary practices, addressing the health and well-being of animals.
Elanco operates in critical markets like pet health and livestock agriculture, focusing on disease prevention and food safety. The company emphasizes sustainable practices to enhance productivity for farmers while maintaining high animal health standards. Originating as a division of Eli Lilly, Elanco has established itself as a key player in the animal health industry.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
9,000
CEO
Mr. Jeffrey N. Simmons
Country
United States
IPO Year
2018
Website
www.elanco.comElanco Animal Health Inc. (ELAN) Latest News & Analysis
Bronstein, Gewirtz & Grossman, LLC is investigating claims for investors who purchased Elanco Animal Health (NYSE:ELAN) securities before November 7, 2023. Visit bgandg.com/ELAN for more information.
The investigation may indicate potential legal issues or financial discrepancies at Elanco, which could impact stock performance and investor confidence.
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims for Elanco Animal Health investors who purchased shares before November 7, 2023. Interested parties can find more info at bgandg.com/ELAN.
The investigation may indicate potential legal issues for Elanco, affecting its stock value and investor sentiment, which could lead to volatility or losses for current shareholders.
Bronstein, Gewirtz & Grossman, LLC is investigating claims for investors who bought Elanco Animal Health (NYSE:ELAN) securities before November 7, 2023. Interested parties can visit bgandg.com/ELAN.
The investigation into Elanco may indicate potential legal issues or financial irregularities, which could impact stock performance and investor confidence.
Bronstein, Gewirtz & Grossman, LLC is investigating claims for investors of Elanco Animal Health (NYSE:ELAN) who purchased shares before November 7, 2023. More info at bgandg.com/ELAN.
The investigation into Elanco may indicate potential legal issues or financial irregularities, which could impact the stock's value and investor sentiment significantly.
Elanco Animal Health will reduce its Board of Directors to 11 members by the 2025 Annual Meeting of Shareholders, as announced on March 17, 2025.
Board changes can signal shifts in company strategy or governance, potentially impacting investor confidence and stock performance. Monitoring these changes is crucial for assessing future direction.
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims for Elanco Animal Health investors who bought securities before November 7, 2023. Further details are available at their website.
The investigation into Elanco may indicate potential legal or financial issues, which could impact stock performance and investor confidence, affecting share prices for those holding the securities.
Frequently Asked Questions About ELAN Stock
What is Elanco Animal Health Inc.'s (ELAN) stock forecast for 2025?
Based on our analysis of 13 Wall Street analysts, Elanco Animal Health Inc. (ELAN) has a median price target of $15.00. The highest price target is $18.00 and the lowest is $12.00.
Is ELAN stock a good investment in 2025?
According to current analyst ratings, ELAN has 8 Buy ratings, 7 Hold ratings, and 0 Sell ratings. The stock is currently trading at $10.55. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ELAN stock?
Wall Street analysts predict ELAN stock could reach $15.00 in the next 12 months. This represents a 42.2% increase from the current price of $10.55. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Elanco Animal Health Inc.'s business model?
Elanco generates revenue by developing and manufacturing a variety of therapeutic and preventative products for pets and livestock. The company offers medicines, vaccines, and wellness products that are essential for veterinary practices, addressing the health and well-being of animals.
What is the highest forecasted price for ELAN Elanco Animal Health Inc.?
The highest price target for ELAN is $18.00 from Jonathan Block at Stifel, which represents a 70.6% increase from the current price of $10.55.
What is the lowest forecasted price for ELAN Elanco Animal Health Inc.?
The lowest price target for ELAN is $12.00 from David Westenberg at Piper Sandler, which represents a 13.7% increase from the current price of $10.55.
What is the overall ELAN consensus from analysts for Elanco Animal Health Inc.?
The overall analyst consensus for ELAN is bullish. Out of 13 Wall Street analysts, 8 rate it as Buy, 7 as Hold, and 0 as Sell, with a median price target of $15.00.
How accurate are ELAN stock price projections?
Stock price projections, including those for Elanco Animal Health Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
